The disposition of ketoconazole was characterized in the rat over a wide dose/concentration range. Bolus dose (0.03-10 mg/kg) studies indicate that plasma concentration-time profiles for ketoconazole are not superimposable when dose normalized because of nonlinearities occurring in both volume of distribution and clearance. The volume of distribution decreases from 3 to less than 1 L/kg, while the plasma clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated. From these results, infusion rates were calculated to maintain the plasma concentrations achieved with particular bolus doses. The curvilinear relationship between steady-state plasma concentration (0.015-8.3 mg/L) and ketoconazole infusion rate (0.021-2.45 mg/hr/kg) was analyzed in terms of Michaelis-Menten kinetics. A Vmax of 3.2 mg/hr/kg and Km of 2.1 mg/L were obtained by nonlinear regression analysis. At the end of the ketoconazole infusion, liver, adrenals and kidneys were removed and assayed for ketoconazole. Tissue-to-plasma partition coefficients for the liver and adrenals showed a marked dependence upon steady-state plasma concentration. Both parameters (liver, 22; and adrenals, 53) showed a decrease of approximately 10-fold as the plasma concentrations were increased. In contrast, the kidney:plasma partition coefficient (1.8), blood:plasma concentration ratio (0.6), and plasma binding (96%) of ketoconazole did not show a concentration dependence over the range studied. It is concluded that the liver is an important determinant of ketoconazole's volume of distribution and that saturation of this process accounts largely for the reduction in volume of distribution with increasing dose.(ABSTRACT TRUNCATED AT 250 WORDS)
Male Sprague-Dawley r a t s (n=181 r e c e i v e d [ N -m e '~h y l -'~C ) -a n t i p y r i n e [25mg/kg; 10uCi/kg; i . p . 1 and were housed i n a l l -g l a s s m e t a b o l i s m cages which a l l o w e d t h e c o n t i n u o u s c o l l e c t i o n o f I 4 C O 2 ( d e r i v e d f r o m N -q r p e t h y l a t i o n l and urine.. h a l f -l i f e o f a n t i p y r i n e was e s t i m a t e d f r o m t h e C02 e x h a l a t i o n r a t e [CERI-time p r o f i l e . A n i m a l s were d i v i d e d i n t o 4 groups and each r a t t e s t e d b e f o r e , and a t v a r y i n g t i m e s up t o 15 days w h i l e r e c e i v i n g d a i l y o r a l doses o f c o r n o i l (5ml/kg1 a l o n e o r t o g e t h e r w i t h DEHP (0.5, 1 o r 2g/kgl. On t h e day a f t e r t h e 1 5 t h dose t h e r a t s were k i l l e d , l i v e r s removed f o r p r e p a r a t i o n o f microsomes by s t a n d a r d d i f f e r e n t i a l c e n t r i f u g a t i o n . The d a t a shown i n t a b l e 1 demonstrates t h a t a t each of t h e doses s t u d i e d t h e r e i s l i v e r enlargement and an i n c r e a s e i n t w o microsomal markers o f d r u g m e t a b o l i s i n g C a p a c i t ycytochrome P450 c o n t e n t and ethoxycoumarin 0 -d e e t h y l a s e .I n c o n t r a s t t h e a n t i p y r i n e CER h a l f -l i f e i s a f f e c t e d o n l y a t t h e h i g h e s t dose. The maximal r e d u c t i o n i n h a l f -l i f e f o l l o w i n g OEHP dosing, w h i c h i s c o n s i d e r a b l y less t h a n t h a t observed w i t h o t h e r c l a s s i c i n d u c e r s (Rhodes & Houston 19831 i s maximal a t 7 days and m a i n t a i n e d u n t i l day 15. any o t h e r cytochromes i n d u c i b l e by OEHP do n o t show a s t r o n g a f f i n i t y f o r a n t i -P Y r i n e as a s u b s t r a t e . A l t h o u g h a d d i t i o n a l s t u d i e s employing o t h e r d r u g s u b s t r a t e s a r e r e q u i r e d , t h e p r e s e n t i n v e s t i g a t i o n would i n d i c a t e l i m i t e d consequences o f DEHP i n d u c t i o n on in v i v o metabolism.Table I ( g / k g l Day 0 Day 1 5 [ % o f body [ nmoles/mg 0 -d e e t h y l a s e 0 1 2 5 i 7 126 * 11 3.4 i 0.2 0.345 2 0.074 0.657 i 0.131 b 1 117 i 7 110 2 9 5.4 ? O.Za 0.396 f 0.154 0.825 k 0,195 2 128 i 26 101 ? 17' 5.7 i 0.4a 0.496 i 0.042a 1,076 i 0.105aThe I t would appear t h a t cytochrome P-452 and E f f e c t s o f v a r i o u s doses o f DEHP on d r u g m e t a b o l i s i n g c a p a c i t y
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.